Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2011-05-25 Regulatory Filings
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
UCB plant eerste anti-TNF vergelijkende studie van Cimzia® (certolizumab pegol) en Humira®* (adalimumab)
Regulatory Filings Classification · 90% confidence The document is a press release, dated May 25th, announcing UCB's plan to start a comparative clinical study for their drug Cimzia® against Humira® for Rheumatoid Arthritis (RA). It contains key highlights, quotes from management (Chief Medical Officer), and information about the drug and the company. It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or a transcript (CT). It is an announcement of future activity/results, which often falls under general regulatory announcements or earnings-related news. Since it is a press release detailing financial/operational news (drug development/trials) but is not explicitly an Earnings Release (ER) which focuses on period results, nor a specific regulatory filing like DIRS or DIV, the most appropriate classification for a corporate announcement of this nature, especially one detailing clinical plans, is often the general 'Regulatory Filings' (RNS) or potentially an 'Earnings Release' (ER) if it were tied to a reporting period. Given the content is a forward-looking announcement about a clinical trial plan, and it is not a formal financial statement, 'RNS' (Regulatory Filings/General Announcement) is the best fit among the provided options, as it serves as a public disclosure of material information. It is not short enough to be an RPA.
2011-05-25 Dutch
110519_Acquisition of own shares_ENG.pdf
Transaction in Own Shares Classification · 99% confidence The document explicitly details the 'Acquisition of own shares by UCB SA/NV' and provides a table listing the dates, amounts, and prices of shares acquired on the Brussels stock exchange. It also mentions an over-the-counter acquisition and the resulting change in the weighted average number of ordinary shares. This content directly corresponds to the definition of a Transaction in Own Shares (share repurchase/issuance), which maps to the code POS.
2011-05-19 English
110519_Acquisition of own shares_FR.pdf
Transaction in Own Shares Classification · 99% confidence The document is titled "Acquisition d'actions propres par UCB SA/NV" (Acquisition of own shares by UCB SA/NV) and details the purchase of UCB shares on the stock exchange and off-market transactions. It explicitly mentions the resulting change in the weighted average number of ordinary shares used to calculate earnings per share. This activity directly corresponds to the definition of a company buying back or selling its own shares, which is classified as 'Transaction in Own Shares'. The corresponding code is POS.
2011-05-19 French
110519_Acquisition of own shares_NL.pdf
Transaction in Own Shares Classification · 98% confidence The document is titled 'Aankoop van eigen aandelen door UCB SA/NV' (Purchase of own shares by UCB SA/NV) and details specific transactions where the company bought back its own shares on the Brussels stock exchange over several dates in May 2011. It explicitly mentions the number of shares purchased and the prices paid. This activity directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase). The filing type code POS matches this description.
2011-05-19 Dutch
110512 shares acquisition_ENG.pdf
Transaction in Own Shares Classification · 99% confidence The document explicitly details the 'Acquisition of own shares in the framework of employees' long-term incentive plans' and provides a table showing the dates, amounts, and prices of UCB shares acquired on the Brussels stock exchange. This activity directly corresponds to the company buying back or transacting its own shares, which aligns perfectly with the definition for 'Transaction in Own Shares' (POS). The document is a direct report of the transaction, not an announcement of a report.
2011-05-12 English
110512 shares acquisition_FR.pdf
Transaction in Own Shares Classification · 98% confidence The document title explicitly mentions 'Acquisition d'actions propres dans le cadre de rémunérations variables' (Acquisition of own shares within the framework of variable remuneration). The text details the number of shares acquired on the stock exchange and states these shares were delivered to personnel exercising stock options. This activity directly corresponds to the company buying back or issuing its own shares, often related to compensation plans. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS). The document length is short (2428 chars), but it is a direct announcement of the transaction itself, not an announcement of a report, thus POS is preferred over RPA/RNS.
2011-05-12 French

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.